Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status | Zendy

Natalie Lowe | Zendy; Jonathan M. Bernstein | Zendy; K. Mais | Zendy; Kate Garcez | Zendy; Lip W. Lee | Zendy; Andrew G. Sykes | Zendy; David Thomson | Zendy; Jarrod J. Homer | Zendy; Catharine West | Zendy; N.J. Slevin | Zendy

Open Access

Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status

Author(s) -

Natalie Lowe,

Jonathan M. Bernstein,

K. Mais,

Kate Garcez,

Lip W. Lee,

Andrew G. Sykes,

David Thomson,

Jarrod J. Homer,

Catharine West,

N.J. Slevin

Publication year - 2017

Publication title -

journal of cancer research and clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.338

H-Index - 94

eISSN - 1432-1335

pISSN - 0171-5216

DOI - 10.1007/s00432-017-2553-9

Subject(s) - medicine , docetaxel , chemoradiotherapy , febrile neutropenia , neutropenia , head and neck cancer , oncology , head and neck squamous cell carcinoma , induction chemotherapy , performance status , fluorouracil , adverse effect , taxane , radiation therapy , regimen , surgery , chemotherapy , cancer , breast cancer

The benefit of adding docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy to chemoradiotherapy (CRT) in head and neck squamous cell carcinoma (HNSCC) remains uncertain. We aimed to investigate whether ICT is well tolerated when given with prophylactic treatment against predicted adverse effects and which patients benefit most.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research